Market Place
Sourcing Support
NRx Pharmaceuticals Reports Q3 & YTD 2024 Results & Update
14 Nov 2024 //
PR NEWSWIRE
NRx Pharma Reschedules Q3 2024 Financial Call to Nov 18
13 Nov 2024 //
PR NEWSWIRE
NRx Pharma to Report Q3 & YTD 2024 Financials on Nov 14
07 Nov 2024 //
PR NEWSWIRE
HOPE Therapeutics & NRx Pharma Sign LOI for Florida Clinics
30 Oct 2024 //
PR NEWSWIRE
NRx Pharmaceuticals and HOPE at ThinkEquity Conference
23 Oct 2024 //
GLOBENEWSWIRE
HOPE therapeutics, NRx Pharma To Acquire Coast Psychiatric Clinic
03 Oct 2024 //
PR NEWSWIRE
NRX-100 (Ketamine) Reaches Stability Milestone
30 Sep 2024 //
CONTRACT PHARMA
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
11 Sep 2024 //
PR NEWSWIRE
NRx, HOPE Therapeutics to Attend H.C. Wainwright Global Investment Conference
03 Sep 2024 //
PR NEWSWIRE
HOPE Therapeutics And NRx Announce $30M Acquisition Of Psychiatry Clinics
26 Aug 2024 //
PR NEWSWIRE
NRx Reports Q2 2024 Results And Provides Business Update
14 Aug 2024 //
PR NEWSWIRE
NRx Pharma Announces Up To $16M Debt Financing From Anson Funds
13 Aug 2024 //
PR NEWSWIRE
NRx Pharmaceuticals To Report Q2 2024 Results On August 14
13 Aug 2024 //
PR NEWSWIRE
HOPE And NRx Align With FDA On Pediatric Study Plan For NRX-100 (Ketamine)
29 Jul 2024 //
PR NEWSWIRE
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
01 Jul 2024 //
PR NEWSWIRE
NRx Pharmaceuticals To Attend HC Wainwright Neuro Perspectives Conference
20 Jun 2024 //
PR NEWSWIRE
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
10 Jun 2024 //
PR NEWSWIRE
NRx Pharmaceuticals Presents Landmark NRX-101 Trial For Suicidal Bipolar
28 May 2024 //
PR NEWSWIRE
NRx Pharma Reports Q1 2024 Results, Business Update
14 May 2024 //
PR NEWSWIRE
NRx Eyes First Revenue In 2024, Announces Breakthroughs
08 May 2024 //
ACCESSWIRE
NRx Pharmaceuticals To Participate In EF Hutton Global Conference
08 May 2024 //
PR NEWSWIRE
NRx Pharmaceuticals Q1 2024 Results On May 14
07 May 2024 //
PR NEWSWIRE
NRx Pharmaceuticals reports superior safety of NRX-101 in depression
06 May 2024 //
PR NEWSWIRE
NRx keeps antidepressant`s blockbuster hopes alive despite flop
30 Apr 2024 //
FIERCE BIOTECH
NRX Announces $2M Underwritten Public Offering Pricing
18 Apr 2024 //
PR NEWSWIRE
NRXP Regains Nasdaq Compliance With Minimum Bid Price Rule
18 Apr 2024 //
PR NEWSWIRE
NRx Pharma Data Shows NRX-101 Avoids C. Diff Risks in Rodents
17 Apr 2024 //
PR NEWSWIRE
NRx Inc. Announces Proposed Underwritten Public Offering of Common Stock
17 Apr 2024 //
PR NEWSWIRE
NRx Develops New HTX-100 (IV Ketamine) Formulation
15 Apr 2024 //
PR NEWSWIRE
NRx Announces Ph 2b/3 Trial of NRX-101 in Suicidal Treatment RBD
08 Apr 2024 //
PR NEWSWIRE
NRx Reports Fourth Quarter and Full Year 2023 Financial Results
01 Apr 2024 //
PR NEWSWIRE
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
28 Mar 2024 //
PR NEWSWIRE
NRx Pharmaceuticals Reports Preliminary Fourth Quarter & FY23 Financial Results
28 Mar 2024 //
PR NEWSWIRE
UPDATE: NRx Pharmaceuticals to Report Q4 and FY23 Financial Results
26 Mar 2024 //
PR NEWSWIRE
NRx Chairman Dr. Javitt to Present at the Ketamine 2024 Conference UK
25 Mar 2024 //
PR NEWSWIRE
NRx Announces Results of the Vote Held During the Meeting of Shareholders
21 Mar 2024 //
PR NEWSWIRE
NRx Pharmaceuticals to Report Fourth Quarter and FY 2023 Financial Results
21 Mar 2024 //
PR NEWSWIRE
NRx Pharma Announces Plan to Distribute Shares of HOPE Therapeutics
18 Mar 2024 //
PR NEWSWIRE
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
12 Mar 2024 //
PR NEWSWIRE
NRx Pharma Completes Memorandum of Understanding for HTX-100 (IV Ketamine)
11 Mar 2024 //
PR NEWSWIRE
NRx Pharma Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101
04 Mar 2024 //
PR NEWSWIRE
NRx Pharmaceuticals Announces Definitive Purchase Agreement f
01 Mar 2024 //
PR NEWSWIRE
NRx Pharmaceuticals Launches HOPE Therapeutics, Inc.
26 Feb 2024 //
PR NEWSWIRE
NRx Announces Proposed Underwritten Public Offering of Common Stock
26 Feb 2024 //
PR NEWSWIRE
NRx Pharma to Launch HOPE Therapeutics at BIO CEO & Investor Conference 2024
20 Feb 2024 //
PR NEWSWIRE
NRx Pharma Announces Advance of $5 Million Milestone Payment from Alvogen
11 Feb 2024 //
PR NEWSWIRE
NRx Pharmaceuticals Reports Comments by Strategic Partner Lotus Pharmaceutical
09 Feb 2024 //
PR NEWSWIRE
NRx Pharma Announces the Incorporation of HOPE Therapeutics
05 Feb 2024 //
PR NEWSWIRE
NRx Pharma Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101
22 Jan 2024 //
PR NEWSWIRE
NRx Pharma Announces Receipt of Positive Nasdaq Listing Determination
17 Jan 2024 //
PR NEWSWIRE
NRx Pharma Announces FDA QIDP and Fast Track Designation of NRX-101
16 Jan 2024 //
PR NEWSWIRE
NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard
02 Jan 2024 //
PR NEWSWIRE
NRx Pharma Announces the Election of Janet Rehnquist to its Board of Directors
27 Dec 2023 //
PR NEWSWIRE
NRx Pharma Announces Signing of Agreement with Columbia University
19 Dec 2023 //
PR NEWSWIRE
NRx Pharmaceuticals Announces FDA Clearance of IND Application for NRX-101
18 Dec 2023 //
PR NEWSWIRE
NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders
13 Dec 2023 //
PR NEWSWIRE
NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event
11 Dec 2023 //
PR NEWSWIRE
NRx Pharmaceuticals to Present at Noble Capital Markets` 19th Annual Conference
27 Nov 2023 //
PR NEWSWIRE
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
PR NEWSWIRE
NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results
07 Nov 2023 //
PR NEWSWIRE
